Filtered By:
Drug: Lipitor
Education: Study

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 785 results found since Jan 2013.

New Studies Give Mixed Results About Taking Fish Oil and Vitamin D
(CHICAGO) — Taking fish oil or vitamin D? Big studies give long-awaited answers on who does and does not benefit from these popular nutrients. Fish oil taken by healthy people, at a dose found in many supplements, showed no clear ability to lower heart or cancer risks. Same for vitamin D. But higher amounts of a purified, prescription fish oil slashed heart problems and heart-related deaths among people with high triglycerides, a type of fat in the blood, and other risks for heart disease. Doctors cheered the results and said they could suggest a new treatment option for hundreds of thousands of patients like these. ...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized onetime Supplements Source Type: news

Mortality and Associated Morbidities Following Traumatic Brain Injury in Older Medicare Statin Users
Conclusion: These findings provide valuable information for clinicians treating older adults with TBI as clinicians can consider, when appropriate, atorvastatin and simvastatin to older adults with TBI in order to decrease mortality and associated morbidities.
Source: The Journal of Head Trauma Rehabilitation - November 1, 2018 Category: Neurology Tags: Focus on Clinical Research and Practice Source Type: research

ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses
This study aimed to assess the association between the angiopoietin-like protein 4 gene (ANGPTL4) single nucleotide polymorphisms (SNPs) and serum lipid levels, the risk of coronary artery disease (CAD) and ische...
Source: Nutrition and Metabolism - October 5, 2018 Category: Nutrition Authors: Qian Yang, Rui-Xing Yin, Xiao-Li Cao, Feng Huang, Yi-Jiang Zhou and Wu-Xian Chen Tags: Research Source Type: research

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
Publication date: Available online 26 August 2018Source: The LancetAuthor(s): Ajay Gupta, Judith Mackay, Andrew Whitehouse, Thomas Godec, Tim Collier, Stuart Pocock, Neil Poulter, Peter SeverSummaryBackgroundIn patients with hypertension, the long-term cardiovascular and all-cause mortality effects of different blood pressure-lowering regimens and lipid-lowering treatment are not well documented, particularly in clinical trial settings. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study reports mortality outcomes after 16 years of follow-up of the UK participants in the original ASCOT trial.MethodsASCOT was...
Source: The Lancet - August 26, 2018 Category: General Medicine Source Type: research

Fractal dimension based carotid plaque characterization from three-dimensional ultrasound images
AbstractIrregularity of the plaque surface associated with previous plaque rupture plays an important role in the risk estimation of stroke caused by carotid atherosclerotic lesions. Thus, the aim of this study is to develop and validate novel vulnerability biomarkers from three-dimensional ultrasound (3DUS) images by analyzing the surface morphological characteristics of carotid plaque using fractal geometry features. In the experiments, a total of 38 3DUS plaque images were obtained from two groups of patients treated with 80  mg of atorvastatin or placebo daily for 3 months respectively. Two types of 3D fractal dimens...
Source: Medical and Biological Engineering and Computing - July 26, 2018 Category: Biomedical Engineering Source Type: research

High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
ConclusionsAmong clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment.Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075.ResumenIntroducción y objetivosLa vigente guía de práctica clínica para el tratamiento de la hipercolesterolemia recomienda mantener la terapia intensiva con estatinas de los pacientes tratados con implante de stent farmacoactivo (SFA). Sin embargo, el tratamiento intensivo con estatinas, una vez estabilizado el paciente, con fre...
Source: Revista Espanola de Cardiologia - July 10, 2018 Category: Cardiology Source Type: research

Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish.
Abstract Impaired vascular integrity leads to serious cerebral vascular diseases such as intracerebral hemorrhage (ICH). In addition, high-dose statin therapy is suggested to cause increased ICH risk due to unclear effects of general inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) on the vascular system. Here we evaluated the protective effects of sodium tanshinone IIA sulfonate (STS), which has high efficacy and safety in clinical studies of ischemic stroke, by using atorvastatin (Ator) induced ICH zebrafish embryos and human umbilical vein endothelial cells (HUVECs). By using double transgenic Tg(...
Source: Toxicology and Applied Pharmacology - May 3, 2018 Category: Toxicology Authors: Zhou ZY, Huang B, Li S, Huang XH, Tang JY, Kwan YW, Hoi PM, Lee SM Tags: Toxicol Appl Pharmacol Source Type: research

This Cholesterol Drug Combination Might Lower Your Risk of Death, Study Finds
(ORLANDO) — A newer cholesterol drug, used with older statin medicines, modestly lowered heart risks and deaths in a big study of heart attack survivors that might persuade insurers to cover the pricey treatment more often. Results on the drug, Praluent, were announced Saturday at an American College of Cardiology conference in Florida. It’s the first time a cholesterol-lowering drug has reduced deaths since statins such as Lipitor and Crestor came out decades ago. “It’s the ultimate outcome; it’s what matters to patients,” said study leader Dr. Philippe Gabriel Steg of Hospital Bichat i...
Source: TIME: Health - March 10, 2018 Category: Consumer Health News Authors: Marilyn Marchione / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news

Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population.
Abstract PURPOSE: Ischemic stroke (IS) is one of the most common neurologic diseases and is the main cause of death and disability in the Chinese population. This retrospective cohort study was performed to elucidate the relationship between single nucleotide polymorphisms (SNPs) in cytochrome P450 genes and the therapeutic effect of atorvastatin. METHODS: A total of 192 cases of IS were enrolled in the study. All patients were treated with atorvastatin, and their lipid levels and proportions were measured. Six SNPs in 4 cytochrome P450 genes (CYP2C19, CYP2D6, CYP3A4, and CYP4F2) related to drug metabolism we...
Source: Clinical Therapeutics - February 27, 2018 Category: Drugs & Pharmacology Authors: Peng C, Ding Y, Yi X, Shen Y, Dong Z, Cao L, Li Q, Ren H, He L, Zhou D, Chen X Tags: Clin Ther Source Type: research

Rationale and Design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial
Publication date: Available online 8 January 2018 Source:American Heart Journal Author(s): Otavio Berwanger, Pedro G.M. de Barros e Silva, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, Carlos Eduardo Bosso, José Mangione, Carisi Anne Polanczyk, Amanda Sousa, Renato Kalil, Luciano de Moura Santos, Andrei C. Sposito, Rafael L. Rech, Antonio Carlos Sobral Sousa, Felipe Baldissera, Bruno Ramos Nascimento, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lucas Petri Daminani, Ligia N Laranjeira, Juliana A Borges de Oliveira, Roberto R Giraldez, Alexandre Biasi Cavalcanti, Sab...
Source: American Heart Journal - January 9, 2018 Category: Cardiology Source Type: research

The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
CONCLUSIONS: The results of our study demonstrated that when added to statin therapy, EZE resulted in improved cardiovascular outcomes, and the response to atorvastatin and EZE combination was similar for both men and women. PMID: 28553847 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - December 6, 2017 Category: Cardiology Authors: Japaridze L, Sadunishvili M Tags: Kardiol Pol Source Type: research

Association between the   TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy.
This study aimed to determine the TIMD4-HAVCR1 variants, their haplotypes and gene-environment interactions on serum lipid levels, the risk of CHD and IS, and the lipid-lowering efficacy of atorvastatin in a southern Chinese Han population. Genotypes of 3 variants in 622 controls, 579 CHD and 546 IS patients were determined by the Snapshot technology. Atorvastatin calcium tablet (20 mg/d) was given in 724 hyperlipidemic patients for 8 weeks after genotyping. The rs12522248 genotypic and allelic frequencies were different between controls and patients, and were associated with the risk of CHD and IS. The rs1501908G-rs125222...
Source: Bioscience Reports - December 5, 2017 Category: Biomedical Science Authors: Zhang QH, Yin RX, Chen WX, Cao XL, Chen YM Tags: Biosci Rep Source Type: research

Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks Clinical Sciences
Background and Purpose—Established risk factors do not fully identify patients at risk for recurrent stroke. The SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) evaluated the effect of atorvastatin on stroke risk in patients with a recent stroke or transient ischemic attack and no known coronary heart disease. This analysis explored the relationships between 13 plasma biomarkers assessed at trial enrollment and the occurrence of outcome strokes.Methods—We conducted a case–cohort study of 2176 participants; 562 had outcome strokes and 1614 were selected randomly from those without outcom...
Source: Stroke - November 27, 2017 Category: Neurology Authors: Peter Ganz, Pierre Amarenco, Larry B. Goldstein, Henrik Sillesen, Weihang Bao, Gregory M. Preston, K. Michael A. Welch Tags: Biomarkers, Proteomics, Cerebrovascular Disease/Stroke Original Contributions Source Type: research

Effect of high-dose atorvastatin therapy accompanied by discontinuation of cholesterol-rich diet on color-doppler ultrasonography parameters of atherosclerotic carotid artery
Aim: Atherosclerosis is the underlying reason for nearly all causes of coronary artery disease and peripheral arterial disease and many cases of stroke. Carotid color-Doppler ultrasonography is a popular tool for evaluating atherosclerosis of the carotid artery. The aim of this study was to generate a rabbit model of carotid arterial atherosclerotic stenosis and the subsequent investigating the effect of high-dose atorvastatin therapy on color-Doppler ultrasonography parameters in this model.
Source: Atherosclerosis - August 1, 2017 Category: Cardiology Authors: Hossein Mehrad, Manijhe Mokhtari-Dizaji, Hossein Ghanaati Source Type: research